Drugs / DoCo-Pro-RBD-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05272605 | Apr 2022 → Apr 2023 | COVID-19 | University of Melbourne | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DoCo-Pro-RBD-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05272605 ↗ |
| Modality | Protein / enzyme biologic | “recombinant protein vaccine” NCT05272605 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT05272605 ↗ |